Human beta-1,4‑Galactosyltransferase 1/B4GalT1 Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB3609
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Gly44-Ser398
Accession # P15291
Specificity
Clonality
Host
Isotype
Applications for Human beta-1,4‑Galactosyltransferase 1/B4GalT1 Antibody
Immunoprecipitation
Sample: Conditioned cell culture medium spiked with Recombinant Human beta4GalT1/
beta‑1,4-Galactosyltransferase 1 (Catalog # 3609-GT), see our available Western blot detection antibodies
Western Blot
Sample: Recombinant Human beta4GalT1/ beta-1,4-Galactosyltransferase 1 (Catalog # 3609-GT)
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: beta-1,4-Galactosyltransferase 1/B4GalT1
beta4GalT1 is one of seven beta1,4 galactosyltransferases that transfer galactose in a beta1,4 linkage to acceptor sugars including GlcNAc, and Glc, and Xyl. By sequence similarity, the beta4GalTs form four groups: beta4GalT1 and beta4GalT2, beta4GalT3 and beta4GalT4, beta4GalT5 and beta4GalT6, and beta4GalT7 (1). beta4GalT1 is unique among the seven enzymes because it can be expressed either as membrane associated form or secreted form (2). The secreted form is restricted to lactating mammary tissues where the enzyme forms a heterodimer with alpha-lactalbumin to catalyze the synthesis of lactose (3). The membrane form can reside either in the Golgi apparatus, where it adds galactose to N-acetylglucosamine residues, or on cell surface, where it functions as a recognition molecule during a variety of cell to cell and cell to matrix interactions, by binding to specific oligosaccharide ligands on opposing cells or in the extracellular matrix (4). The two enzymatic forms result from alternate transcription initiation sites and post-translational processing (5). Defects in beta4GalT1 are the cause of congenital disorder of glycosylation type 2D (CDG2D) (6). The amino acid sequence of human B4GALT1 is 88%, 87% and 71% identical to that of rat, mouse/canine and chicken.
References
- Amado, M. et al. (1999) Biochim. Biophys. Acta. 1473:35.
- Yamaguchi, N and Fukuda, M.N. (1995) J. Biol. Chem. 270:12170.
- Appert, H.E. et al. (1986) Biochem. Biophys. Res. Commun. 138:224.
- Lopez, L.C. et al. (1991) J. Biol. Chem. 266:15984.
- Mengle-Gaw, L. et al. (1991) Biochem. Biophys. Res. Commun. 176:1269.
- Hansske, B. et al. (2002) J. Clin. Invest. 109:725.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional beta-1,4-Galactosyltransferase 1/B4GalT1 Products
Product Documents for Human beta-1,4‑Galactosyltransferase 1/B4GalT1 Antibody
Product Specific Notices for Human beta-1,4‑Galactosyltransferase 1/B4GalT1 Antibody
For research use only